

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: PanGenomic Health Inc. ("PanGenomic", the "Company" or the "Issuer").

Trading Symbol: NARA

Number of Outstanding Listed Securities: 71,615,972

Date: August 8, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

PanGenomic is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Our initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

PanGenomic was approved for listing on the CSE on July 15, 2022 with an effective date of July 18, 2022. The escrow release conditions for PanGenomic's recently completed financing of 7,365,999 subscription receipts (the "Subscription Receipts") at a price of \$0.15 per Subscription Receipt for total gross proceeds of \$1,104,900 (the "Financing") have been satisfied and the proceeds from the Financing have been released from escrow, as further described in Item 2 below.

PanGenomic engaged Meus Management Inc. ("Meus") to provide capital markets advisory, investor relations and corporate strategy services. In addition, PanGenomic has engaged Generation IACP Inc. ("Generation IACP") to provide market making services in accordance with the policies of the Canadian Securities Exchange (the "CSE"), as further described in Item 2 below.

2. Provide a general overview and discussion of the activities of management.

During the month of July 2022 management activities included:

PanGenomic was approved for listing on the CSE on July 15, 2022 with an effective date of July 18, 2022.

The escrow release conditions for PanGenomic's recently completed financing of 7,365,999 Subscription Receipts at a price of \$0.15 per Subscription Receipt for total gross proceeds of \$1,104,900 have been satisfied and the proceeds from the Financing have been released from escrow. Upon satisfaction of the escrow release conditions, each Subscription Receipt was automatically exchanged for one Unit consisting of one Common Share and one Warrant. Each Warrant is exercisable at a price of \$0.30 per share for a period of 24 months following conversion of the Subscription Receipts, subject to acceleration. The net proceeds of the Financing will be used for the development and releases of PanGenomic's Nara App (Phases 2 and 3) and PlantGx Platform (Phase 2), marketing and investor relations expenses, expenses related to the Prospectus and the Listing, general and administrative expenses and general working capital purposes.

PanGenomic engaged Meus to provide capital markets advisory, investor relations and corporate strategy services. In addition, PanGenomic has engaged Generation IACP to provide market making services in accordance with the policies of the CSE. PanGenomic will pay Meus, based in Richmond, BC, a monthly fee of \$5,000, and will issue to Meus Management options to purchase up to 30,000 Class A Common shares (the "Common Shares") exercisable at a price of \$0.25 per share for a period of 24 months from the date of issuance, with one-half of the options vesting upon Meus' engagement and one-half of the options vesting three months thereafter. Meus is expected to provide its services commencing July 20, 2022 until terminated by PanGenomic. Generation IACP, based in Toronto, ON, will trade the Common Shares on the CSE with the objective of contributing to the market liquidity of the Common Shares. PanGenomic will pay Generation IACP a monthly fee of \$7,500, payable quarterly, with such fee subject to an annual increases of 3%. Generation IACP is expected to provide the services for an initial six month term commencing July 18, 2022, automatically renewing for successive six month terms unless terminated by PanGenomic.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs

and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The core products offered by the Company are the Nara App and the PlantGx Platform. The Nara App is a mobile app that will provide consumers with a knowledge base tailored to an individual's unique user profile, leveraging input from mental health questionnaires, current drug treatment regimen, genomic sequence analysis, as well as their protein and microbiome biomarker reports. The PlantGx Platform is being developed to provide health practitioners with access to the consumer's Nara App data and their diagnostic reports. This enhances identification of appropriate natural remedy treatments and allows practitioners to track their patient's natural treatment progress and effectiveness. The Company's planned lab based services will provide health practitioners with access to a proprietary panel of genetic and protein biomarkers that will be developed to assist in tracking patient response to natural treatments.

The Nara App and PlantGx Platform will provide information about natural remedy treatments for mental health conditions, such as anxiety and depression. The Company's Platform obtains such information from third party clinical studies and other online research sources. Natural remedies can include any plant-based medicines for which there is third party research information about the efficacy and safety of such natural remedies for the treatment of mental health conditions. The Company expects most information displayed on the Platform to pertain to traditional herbal remedies, examples of which include Rhodiola Rosea, St. John's Wort, Ginkgo Biloba and Lavender. As research becomes available about the treatment of mental health conditions using controlled substances that are natural, such as psilocybe mushrooms, any such research information would also be available on the platform with appropriate disclosures about their legality in the applicable jurisdiction.

The Nara App is currently available through the Google Play Store and the Apple App Store. The PlantGx Platform is expected to be made available to health practitioners in the fourth quarter of 2022.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of July 2022.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

PanGenomic engaged Meus to provide capital markets advisory, investor relations and corporate strategy services and Generation IACP to provide market making services in accordance with the policies of the CSE, as further described in Items 1 and 2 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no expiry or termination of any contracts or agreements between the PanGenomic, PanGenomic's affiliates or third parties or cancellation of any financing arrangements during the month of July 2022.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There was no acquisition or disposition of PanGenomic assets that occurred during the month of July 2022.

8. Describe the acquisition of new customers or loss of customers.

There was no acquisition or disposition of customers during the month of July 2022.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products during the month of July 2022.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of July 2022.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of July 2022.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of July 2022.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There were no indebtedness incurred or repaid during the month of July 2022.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common Shares	7,365,999	Outlined above in items 1 and 2	Outlined above in items 1 and 2
Warrants	7,365,999	7,365,999 warrants were issued at \$0.30	N/A
Stock Options	30,000	30,000 stock options were issued at \$0.25	N/A

(1) *State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons during the month of July 2022.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members during the month of July 2022.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Form 2A Listing Statement dated as July 13, 2022 under the headings "Risks Factors". The Form 2A Listing Statement is available on the Issuer's on the Issuer's disclosure hall with the CSE at [www.thecse.com](http://www.thecse.com).

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 8, 2022.

Vincent Lum  
Name of Director or Senior Officer

"Vincent Lum"  
Signature

CEO and Director  
Official Capacity

<b>Issuer Details</b> Name of Issuer <b>PanGenomic Health Inc.</b>	For Month End <b>July 2022</b>	Date of Report YY/MM/D 22/08/08
Issuer Address 102 – 3800 Wesbrook Mall		
City/Province/Postal Code Vancouver, BC, V6S 2L9	Issuer Fax No. N/A	Issuer Telephone No. 1 (778) 743-4642
Contact Name <b>Vincent Lum</b>	Contact Position <b>CEO and Director</b>	Contact Telephone No. 1 (778) 743-4642
Contact Email Address <a href="mailto:vincent@pangenomic.com">vincent@pangenomic.com</a>	Web Site Address <a href="http://www.pangenomic.com">www.pangenomic.com</a>	